COM4S_M.TTF

Senior Scientist, Ordway Research Institute
Associate Director of Cancer Center, Ordway Research Institute
Adjunct Associate Professor of Medicine, Albany Medical College

Contact
  • Molecular Oncology Laboratory
    • Work: (518) 641-6470
    • Fax: (518) 641-6305


Back to Investigator Profiles

Research Focus

Dr. Broude’s team is studying cellular and molecular mechanisms of mitotic catastrophe induced by DNA-damaging agents and cyclin-dependent kinase inhibitors, in normal and tumor cells that differ in the status of different cell cycle checkpoints.

Mitotic catastrophe – defined as cell death that occurs as a consequence of abnormal mitosis – is one of the principal antiproliferative effects of almost all anticancer agents, regardless of whether such agents affect the cell cycle in mitosis or in interphase. Normal cells avoid mitotic catastrophe by activating different cell cycle checkpoints, which allow the cell to repair the damage prior to entering mitosis. Tumor cells, however, are always deficient in some of the cell cycle checkpoints. This deficiency increases the likelihood that tumor cells would enter mitosis before repairing the damage and thereby undergo mitotic catastrophe. In contrast to treatment-induced physiological antiproliferative responses, such as apoptosis and senescence, mitotic catastrophe is potentiated rather than inhibited by cellular changes that develop in the course of neoplastic transformation. It is therefore a major mechanism of tumor selectivity for clinically useful anticancer agents.

The analysis of mitotic catastrophe by Dr. Broude’s team involves:

Elucidation of the mechanisms of treatment-induced mitotic catastrophe in tumor cells should help in developing new drugs and improving the efficacy of existing anticancer agents.

Selected Publications
Ordway Research Institute © 2007
150 New Scotland Avenue
Albany, New York 12208
Contact Us